Nonadherence in Nearly One-Third of Patients With HTN

Share this content:
Nonadherence in Nearly One-Third of Patients With HTN
Nonadherence in Nearly One-Third of Patients With HTN

MONDAY, Nov. 7, 2016 (HealthDay News) -- More than 30 percent of patients with hypertension are not adherent to antihypertensive drug therapy, according to a study published online Nov. 3 in the Journal of Evaluation in Clinical Practice.

Jerome J. Federspiel, M.D., Ph.D., from the University of North Carolina at Chapel Hill, and colleagues linked Atherosclerosis Risk in Communities records to Medicare claims for cohort participants reporting hypertension without prevalent cardiovascular disease. Medicare Part D claims data were used to assess antihypertensive medication adherence, measured as more than 80 percent proportion days covered.

The researchers found that for 31.5 percent of the 1,826 participants with hypertension and Part D coverage there was no antihypertensive class with medication adherence of more than 80 percent proportion days covered in the three months preceding the report of hypertension. Positive predictors of use included female gender and diabetes, after adjustment for confounding variables; African-American race and current smoking were negative predictors. After adjustment, the correlation between receiving no therapy and a composite end point of cardiovascular outcomes through 2012 was not statistically significant; the adjusted associations with Medicare inpatient days or payments were also not statistically significant.

"Despite having medical and prescription coverage, nearly a third of hypertensive participants were not adherent to antihypertensive drug therapy," the authors write. "Differences in clinical outcomes associated with nonadherence, though not statistically significant, were consistent with results from randomized trials."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »